Total Valuation
Prestige BioPharma Limited Korean Deposit Receipt Repr 1/5 Sh has a market cap or net worth of ₩337.14B. The enterprise value is ―.
Market Cap₩337.14B
Enterprise Value―
Share Statistics
Prestige BioPharma Limited Korean Deposit Receipt Repr 1/5 Sh has 60,096,153 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding60,096,153
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Prestige BioPharma Limited Korean Deposit Receipt Repr 1/5 Sh’s return on equity (ROE) is 0.05 and return on invested capital (ROIC) is -9.77%.
Return on Equity (ROE)0.05
Return on Assets (ROA)0.03
Return on Invested Capital (ROIC)-9.77%
Return on Capital Employed (ROCE)-0.12
Revenue Per Employee265.00M
Profits Per Employee412.45M
Employee Count54
Asset Turnover0.02
Inventory Turnover1.43
Valuation Ratios
The current PE Ratio of Prestige BioPharma Limited Korean Deposit Receipt Repr 1/5 Sh is ―. Prestige BioPharma Limited Korean Deposit Receipt Repr 1/5 Sh’s PEG ratio is -0.24.
PE Ratio―
PS Ratio61.73
PB Ratio2.16
Price to Fair Value2.16
Price to FCF-9.30
Price to Operating Cash Flow―
PEG Ratio-0.24
Income Statement
In the last 12 months, Prestige BioPharma Limited Korean Deposit Receipt Repr 1/5 Sh had revenue of 14.31B and earned 22.27B in profits. Earnings per share was 370.61.
Revenue14.31B
Gross Profit-24.01B
Operating Income-67.28B
Pretax Income3.92B
Net Income22.27B
EBITDA33.31B
Earnings Per Share (EPS)370.61
Cash Flow
In the last 12 months, operating cash flow was -53.18B and capital expenditures -41.69B, giving a free cash flow of -94.87B billion.
Operating Cash Flow-53.18B
Free Cash Flow-94.87B
Free Cash Flow per Share-1.58K
Dividends & Yields
Prestige BioPharma Limited Korean Deposit Receipt Repr 1/5 Sh pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta-0.07
52-Week Price Change-61.72%
50-Day Moving Average―
200-Day Moving Average―
Relative Strength Index (RSI)―
Average Volume (3m)67.47K
Important Dates
Prestige BioPharma Limited Korean Deposit Receipt Repr 1/5 Sh upcoming earnings date is Nov 26, 2026, TBA (Confirmed).
Last Earnings DateMay 29, 2026
Next Earnings DateNov 26, 2026
Ex-Dividend Date―
Financial Position
Prestige BioPharma Limited Korean Deposit Receipt Repr 1/5 Sh as a current ratio of 1.27, with Debt / Equity ratio of ―
Current Ratio1.27
Quick Ratio1.11
Debt to Market Cap0.16
Net Debt to EBITDA0.86
Interest Coverage Ratio-8.83
Taxes
In the past 12 months, Prestige BioPharma Limited Korean Deposit Receipt Repr 1/5 Sh has paid -248.20M in taxes.
Income Tax-248.20M
Effective Tax Rate-0.06
Enterprise Valuation
Prestige BioPharma Limited Korean Deposit Receipt Repr 1/5 Sh EV to EBITDA ratio is 27.38, with an EV/FCF ratio of -9.60.
EV to Sales63.75
EV to EBITDA27.38
EV to Free Cash Flow-9.60
EV to Operating Cash Flow-16.79
Balance Sheet
Prestige BioPharma Limited Korean Deposit Receipt Repr 1/5 Sh has ₩166.08B in cash and marketable securities with ₩85.94B in debt, giving a net cash position of ₩22.63B billion.
Cash & Marketable Securities₩166.08B
Total Debt₩85.94B
Net Cash₩22.63B
Net Cash Per Share₩376.52
Tangible Book Value Per Share₩5.21K
Margins
Gross margin is ―, with operating margin of -470.14%, and net profit margin of 155.64%.
Gross Margin―
Operating Margin-470.14%
Pretax Margin27.38%
Net Profit Margin155.64%
EBITDA Margin232.80%
EBIT Margin80.62%
Analyst Forecast
The average price target for Prestige BioPharma Limited Korean Deposit Receipt Repr 1/5 Sh is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast―
EPS Growth Forecast―